{"entity":{"id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","aka":["STAR-121"],"tldr":"A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.","summary":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05502237, led by Gilead Sciences with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumour Aberrations. Planned enrolment is 1021 participants (actual). The study started in 2022-10-12 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05502237","url":"https://clinicaltrials.gov/study/NCT05502237"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","pdl1-high-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["domvanalimab"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05502237","phase":"3","setting":"A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations","sponsor":"Gilead Sciences","participation":[{"nct":"NCT05502237","source":"https://clinicaltrials.gov/study/NCT05502237","fetchedAt":"2026-10-07T16:53:44.279Z","studySha256":"551338fa3022664a4f69fc446b58298c02d048635afa23f3d7e1cb7f15f6b0c6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-30","leadSponsor":"Gilead Sciences","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1021,"enrolmentType":"ACTUAL","siteCount":186,"recruitingSiteCount":0,"countries":["Argentina","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Portugal","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2022-10-12","startedType":"actual","enrolled":1021,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05502237/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"drug":[{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}